Skip to content
Live news Screener Coverage Pricing Docs REST API WebSocket API MCP server Company Use cases Blog Changelog Status Compare Contact
TECK$59.05+0.15(+0.25%)Teck Provides Update on Highland Valley Copper Operations[3:18:56 PM ET]AXON$422.00+7.40(+1.78%)Axon Announces Body 5: Next-Generation Camera Built for the AI Era Axon (Nasdaq: AXON), the global leader in public safety technology, today announced Axon Body 5, its newest body-worn camera designed to bring more...[1:00:00 PM ET]PFE$30.02-0.40(-1.31%)Pfizer's 25-Valent Pediatric Pneumococcal Conjugate Vaccine Candidate Shows Robust Phase 2 Data at IDWeek 2026[11:18:00 AM ET]BIVI$1.24-0.04(-3.13%)From Private Credit to Fusion Power: New to The Street Show #777 Premieres Tonight on Bloomberg Television[10:30:00 AM ET]AMGN$439.26-8.02(-1.79%)IMDELLTRA® IN COMBINATION WITH IMFINZI® REDUCED RISK OF DEATH BY AN UNPRECEDENTED 58% IN FIRST-LINE EXTENSIVE STAGE SMALL CELL LUNG CANCER Amgen (NASDAQ:AMGN) today announced landmark interim Phase 3 results showing that IMDELLTRA® (tarlatamab-dlle) in combination with AstraZeneca's...[10:30:00 AM ET]JNJ$263.81-3.80(-1.42%)Johnson & Johnson announces ERLEADA® (apalutamide) treatment before and after surgery reduces risk of recurrence or death by 62% versus surgery alone in high-risk prostate cancer Johnson & Johnson (NYSE: JNJ) today announced new results from the Phase 3 PROTEUS substudy that directly compared the investigational use of...[8:54:00 AM ET]PBLS$24.79-2.13(-7.91%)Parabilis Medicines Presents Updated Phase 1/2 Data for Zolucatetide Demonstrating Compelling Efficacy and Favorable Safety and Tolerability Profile in Patients with Desmoid Tumors[8:45:00 AM ET]SMTC$131.80+6.68(+5.34%)Semtech Brings 5G Network Slicing, FIPS 140-3 to IACP 2026[8:00:00 AM ET]GMAB$43.85+3.85(+9.63%)Genmab and Incyte Announce Clinical Trial Collaboration in Metastatic Colorectal Cancer[7:00:00 AM ET]INCY$115.00-1.93(-1.65%)Incyte and Genmab Announce Clinical Trial Collaboration in Metastatic Colorectal Cancer[7:00:00 AM ET]NBTX$29.36+0.17(+0.58%)NANOBIOTIX Announces Final Data from Phase 1 Study Evaluating JNJ-1900 (NBTXR3) With Immune Checkpoint Inhibitors as a 2L+ Therapy in Anti-PD-1-Resistant Primary Cutaneous Melanoma[7:00:00 AM ET]ONC$377.63-4.64(-1.21%)BeOne Presents Compelling Data in Hard-to-Treat Liver and Lung Cancers at ESMO 2026[4:15:00 AM ET]CMPX$0.77-0.03(-3.97%)Compass Therapeutics Announces Publication of Phase 2/3 COMPANION-002 Results for Tovecimig in the Journal of Clinical Oncology and Oral Presentation at ESMO 2026[4:15:00 AM ET]CELC$63.20-2.37(-3.61%)Celcuity Presents Updated Results from the PIK3CA MT Cohort of the Phase 3 VIKTORIA-1 Study in Patients with HR+/HER2- Advanced Breast Cancer at the ESMO Congress 2026[4:15:00 AM ET]

TROW · NASDAQ

T. Rowe Price Group, Inc.

$104.10 +0.84 (+0.81%)

Company overview

T. Rowe Price Group, Inc. is a publicly owned investment manager. The firm provides its services to individuals, institutional investors, retirement plans, financial intermediaries, and institutions. It launches and manages equity and fixed income mutual funds. The firm invests in the public equity and fixed income markets across the globe. It employs fundamental and quantitative analysis with a bottom-up approach, utilizing in-house and external research. The firm also employs socially responsible investing with a focus on environmental, social, and governance issues. It makes investments in late-stage venture capital transactions and usually invests between $3 million and $5 million. The firm was previously known as T. Rowe Group, Inc. and T. Rowe Price Associates, Inc. T. Rowe Price Group, Inc. was founded in 1937 and is based in Baltimore, Maryland, with offices worldwide.

Sector
Financial Services
Industry
Asset Management
Exchange
NASDAQ
Market cap
$22.2B
Employees
8,084
Headquarters
Baltimore, MD
CEO
Robert W. Sharps
Listed
April 2, 1986
P/E
11.15
Dividend yield
4.96%

Company financials

Revenue
$7.4B
Gross profit
$5.1B
Operating income
$2.2B
EBITDA
$2.9B
Net income
$2.1B
EPS
$9.34
Total assets
$14.4B
Total debt
$438M
Gross margin
69.05%
Net margin
28.28%
Earnings yield
8.97%

Revenue segmentation

By product (FY 2025)
By region (FY 2025)

No geographic segmentation.

Showing FY 2025

Price chart

95.51102.39109.27116.14123.02
TROW 1D NASDAQ O102.67H104.60L102.26C104.20+0.75 (+0.72%)Vol2.09M

News

15-min delaySigned-out view is delayed 15 minutes. Log in on Pro for the live news desk.

Source
Date
Type
Ticker Type Headline Source Published
TROW Stock news Jim Cramer's Case for “Accidental High Yielders” When the Fed Shakes the Market 24/7 Wall Street
TROW Stock news Better Forecasting Starts With Admitting You're Wrong ETF Trends
TROW Stock news T. Rowe Price (TROW) Expected to Beat Earnings Estimates: What to Know Ahead of Q3 Release Zacks Investment Research
TROW Stock news T. Rowe Price (TROW) Beats Stock Market Upswing: What Investors Need to Know Zacks Investment Research
TROW Stock news Procter & Gamble Has Raised Its Dividend for 70 Years. These 4 Stocks Also Reward Patience 24/7 Wall Street
TROW Stock news BlackRock's $15.3 Trillion Empire Reveals Why These 4 Dividend Stocks Are Worth Watching 24/7 Wall Street
TROW Press release T. ROWE PRICE GROUP REPORTS MONTH-END ASSETS UNDER MANAGEMENT FOR SEPTEMBER 2026 PRNewsWire
TROW Stock news In 1986, He Started Collecting Shopping Carts For $5.85 An Hour. Nearly 40 Years Later, He’s Still Working As A Cashier, And His 401(k) Has Grown To Over $1 Million. The Story Of Tony Barzar Has Important Lessons For Every Investor 247 Wallst
TROW Stock news JPMorgan Just Raised Its Dividend 10%. These 4 Stocks Also Can Afford to Pay Much Bigger Dividends 24/7 Wall Street
TROW Stock news 5 Historically Cheap High-Yield Dividend Stocks Ripe for Income Seekers 24/7 Wall Street
TROW Stock news Critical Analysis: Virtu Financial (NYSE:VIRT) & T. Rowe Price Group (NASDAQ:TROW) Defense World
TROW Stock news Will T. Rowe (TROW) Beat Estimates Again in Its Next Earnings Report? Zacks Investment Research
TROW Stock news T. Rowe Price (TROW) Surpasses Market Returns: Some Facts Worth Knowing Zacks Investment Research
TROW Press release T. ROWE PRICE LAUNCHES DYNAMIC EMERGING MARKETS BOND EXCHANGE TRADED FUND PRNewsWire
TROW Stock news Reinvesting T. Rowe Price's Dividend for 20 Years Changes the Math Completely. The Motley Fool
TROW Stock news Why T. Rowe Price (TROW) is a Top Dividend Stock for Your Portfolio Zacks Investment Research
TROW Stock news T. Rowe Price (TROW) Surpasses Market Returns: Some Facts Worth Knowing Zacks Investment Research
TROW Stock news T. ROWE PRICE EXPLORES WHAT INVESTORS CAN LEARN FROM SHELL CEO'S VIEW OF AN "ENERGY ADDITION" ERA GuruFocus
TROW Stock news T. ROWE PRICE EXPLORES WHAT INVESTORS CAN LEARN FROM SHELL CEO'S VIEW OF AN "ENERGY ADDITION" ERA PRNewsWire
TROW Stock news Why I Took A Starter Position In T. Rowe Price Now Seeking Alpha
FAQ

Questions about T. Rowe Price Group, Inc.

What does T. Rowe Price Group, Inc. do?
T. Rowe Price Group, Inc. is a publicly owned investment manager. The firm provides its services to individuals, institutional investors, retirement plans, financial intermediaries, and institutions. It launches and manages equity and fixed income mutual funds. The firm invests in the public equity and fixed income markets across the globe. It employs fundamental and quantitative analysis with a bottom-up approach, utilizing in-house and external research. The firm also employs socially responsible investing with a focus on environmental, social, and governance issues. It makes investments in late-stage venture capital transactions and usually invests between $3 million and $5 million. The firm was previously known as T. Rowe Group, Inc. and T. Rowe Price Associates, Inc. T. Rowe Price Group, Inc. was founded in 1937 and is based in Baltimore, Maryland, with offices worldwide.
What is TROW's market cap?
T. Rowe Price Group, Inc. (TROW) is a listed stock with a live quote. The latest market cap on this page is $22.2B.
Where is T. Rowe Price Group, Inc. headquartered?
T. Rowe Price Group, Inc. is headquartered in Baltimore, MD.
How do I get TROW news from the API?
Call GET /v1/news?tickers=TROW. Add type=news, type=press_release, or type=legal to take one feed. Pro keys search the full archive in real time. Free keys are delayed 15 minutes and return the last year. Signed-out visitors and Free accounts see that same year on this page. Pro sees the full archive.
How far back does TROW news go?
Signed-out visitors and Free accounts see the last year of stock news, press releases, and legal notices for TROW, 15 minutes behind, and each headline links to the publisher. Pro, including the 7-day trial, sees the full archive as headlines are ingested. A Free API key returns the last year. Pro keys search the full archive.
Is the TROW price on this page from the API?
The price and daily change update during the US session for every visitor. That quote is context on this page. It is not part of the news API. The chart is one candle per session from the start of 2020. 1W, 1M, and 1Y group those sessions.

Real-time stock news for $15 a month.

Start a 7-day Pro trial. A card is required. REST, WebSocket, and MCP are included, with 2,000 REST requests a day. Paid Pro removes the daily cap. If you don't subscribe, the account stays on Free.